ARTICLE | Company News

GSK declines option to Ionis' inotersen

August 11, 2017 10:53 PM UTC

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined its exclusive option to license inotersen ahead of regulatory submissions, which would have triggered a $45 million milestone payment to Ionis. The pharma also declined its option to IONIS-FB-LRx. Ionis said GSK declined its options as part of a reprioritization of its pipeline and strategic review of its rare diseases business.

Ionis and GSK were partnered under an amended 2010 deal to discover and develop up to six therapeutics using Ionis’ antisense technology against rare and serious diseases. ...